pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

DECEMBER 13, 2020

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Pharmaceutical Technology

JULY 29, 2022

However, in patients with urea cycle disorders, genetic defects result in inadequate amounts of the enzymes needed to convert nitrogen into urea. The University of California Los Angeles are currently investigating the use of genetically altered hepatocyte-like cells generated from induced pluripotent stem cells. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. This genetic-led approach will also aid in expediting the approval of new treatments. Innovation.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

NOVEMBER 3, 2020

Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LEXINGTON, Mass., About LogicBio Therapeutics.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genomics 52

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.

Sales 40

Sales Vaccination Vaccine Production 40

Pharmaceutical Technology

MARCH 20, 2023

In APAC, for example, industry commentators are predicting that the pharmaceutical sector’s historic focus on genetics and manufacturing will shift towards cutting-edge technology. One significant growth area is the rise of genomics. But the headline figures are concealing some rising trends.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225